Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Suzhou Connect Biopharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Dermatitis, Atopic|Pulmonary Eosinophilia|Asthma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
SIM0718-301 | P3 |
Not yet recruiting |
Pulmonary Eosinophilia|Asthma |
2027-06-30 |
|
SIM0718-302 | P3 |
Not yet recruiting |
Dermatitis, Atopic |
2025-08-31 |
|
CTR20242195 | N/A |
Unknown |
Asthma |
None |
|
CTR20242160 | N/A |
Unknown |
Dermatitis, Atopic |
None |